Introduction
Neovascular age-related macular degeneration (nAMD) is the most common cause of blindness in the elderly population (Ferris et al. 1984; Hoeg et al. 2016 ) affecting annually 6100 eyes per 1 million inhabitants in the Danish population (Buch et al. 2005) .
Repetitive intravitreal injections of vascular endothelial growth factor (VEGF) inhibitors has demonstrated efficacy (Rosenfeld et al. 2006; Brown et al. 2009; Heier et al. 2012 ), but treatment with frequent and continuously injections is a huge burden for the patients and the health care system.
Multiple mechanisms are involved in the development of nAMD, and hypoxia has been proposed as a central mediator. It stimulates the production of VEGF, which promotes neovascularization and vascular leakage (Folkman & Klagsbrun 1987; Adamis & Shima 2005; Ng & Adamis 2005; Stefansson et al. 2011 ).
Measurement of the retinal oxygen saturation can be performed non-invasively by a spectrophotometric retinal oximeter. In a cross-sectional study, Geirsdottir et al. reported that in patients with treatment-naïve nAMD, retinal oxygen saturation and age were positively correlated as compared to normal controls (Geirsdottir et al. 2014) . This could indicate that the retinal oxygen metabolism is altered in nAMD and that it might serve as a potential biomarker of treatment response.
Previous studies have also investigated structural changes in retinal vessel calibres after VEGF inhibition with ranibizumab or bevacizumab in nAMD (Papadopoulou et al. 2009; Fontaine et al. 2011; Micieli et al. 2012; Tatlipinar et al. 2012; Wickremasinghe et al. 2012; Mendrinos et al. 2013; Pekel et al. 2015 ; Kurt et al. 2017) . Results have been conflicting, and as far as we know, this has not been tested in response to aflibercept treatment, which has replaced ranibizumab and bevacizumab in many centres.
This study aimed to investigate if retinal metabolism and structure as given by retinal vascular oxygen saturation and calibres may be used as non-invasive markers for early treatment response after a loading phase of three monthly intravitreal aflibercept injections in eyes with treatment-naïve nAMD.
Materials and methods

Recruitment of patients
All patients were recruited at the Department of Ophthalmology at Odense University Hospital between October 2016 and January 2017. Patients with treatment-naïve eyes with nAMD were included in the prospective study, and in a cross-sectional comparison, patients with dry AMD as well as eyes without macular disease were recruited for baseline comparison.
Eyes with previous retinal laser treatment of any kind were excluded from the study. All patients were only allowed to participate in the study with one eye. If patients in the non-nAMD groups had two eligible eyes, we included the eye with best image quality (and chose the right eye if there was no difference in image quality). In the prospective study of nAMD, if two eyes were eligible, we included the eye that had follow-up imaging, or if this was obtained in both eyes, we used the same algorithm as for the non-nAMD groups.
Data were collected on age, gender, smoking, diabetes and former cataract surgery. Questions about smoking were divided into four categories: current smokers, smoking cessation <10 years, smoking cessation >10 years, and non-smokers. In the data analysis, the first two groups were combined and defined as the "smoking" group and the last two groups as the "non-smoking" group.
All participants were Caucasian.
Baseline
All examinations were done in eyes dilated with tropicamide 10 mg/ml and phenylephrinhydroclorid 10%. All diagnoses were initially given by trained physicians at the department, based upon ophthalmoscopy and swept source optical coherence tomography (SS OCT) (DRI OCT Triton, Topcon, Tokyo, Japan). If nAMD was suspected, fluorescein and indocyanine green angiography (Heidelberg Spectralis, Heidelberg Engineering, Heidelberg, Germany) were performed. For all patients, the diagnosis was subsequently confirmed by a retinal specialist (JG). Dry AMD were defined as any number of macular drusen or geographic atrophy seen on a disc-centred fundus image.
Best corrected visual acuity (BCVA) was measured according to the Early Treatment Diabetic
Retinopathy Study (ETDRS) scale. Intraocular pressure (IOP) was recorded (Icare tonometer, Icare Finland Oy, Helsinki, Finland), and central retinal thickness was measured by SS OCT.
Non-invasive retinal measurements
Measurement of retinal oxygen saturation and calibre was performed on disc-centred 50° fundus images captured by Oxymap T1 and analysed with the Oxymap Analyser software (Oxymap model T1, Oxymap, software version 2.5.0, Reykjavik, Iceland).
The camera is based on a fundus camera, taking two fundus images simultaneously at two different wavelengths. The 570 nm wavelength image is insensitive to oxygen as opposed to the 600 nm wavelength. By calculating the difference in absorbance of light in the two images, the software measures and visualises the oxygen saturation in one single image using a colour grid on all traced vessels ( Figure 1) (Geirsdottir et al. 2012) .
Two circles were placed on the optic disc centred image. The first circle was manually placed around the edge of the optic disc, 20-35 pixels away from the edge of the disc. This was done to avoid reflection of light from the retinal nerve fibre layer around the disc, as this could influence the measurement of oxygen saturation. The second circle was placed concentric around the first circle, with a diameter at three times the diameter of the first circle. All vessel measurements were done between the inner and the outer circle. In each image, vessel measurements were done on 8 vessels (one retinal arteriole and venule in each quadrant). Vessels larger than 6 μm were automatically detected and traced for a length of 50-200 pixels. Measurements were performed in each vessel from the inner circle until a length of maximum of 200 pixels was reached or to the first branching of the vessel. If the branching occurred before reaching a length of 50 pixels, the branch was measured instead. The software automatically measured the mean retinal vascular oxygen saturation and vascular calibre in each chosen vessel segment. Retinal arteriolar and venular saturation and calibre were defined as the mean of the four arterioles and venules in each image.
Measurements and grading were carried out by the same trained grader (DBJ), according to a predefined protocol. Eyes with an image quality of less than 6.0 (due to blurry media) were excluded from the study.
At follow-up, measurements were repeated at the same vessel-segments that were used at baseline. If a vessel graded at baseline was ungradable at follow-up, the quadrant was left ungraded at follow-up.
Follow-up and outcome measurements
Each eye diagnosed with nAMD received three monthly injections of intravitreal 2.0 mg aflibercept.
Follow-up was conducted approximately one month after the last injection. At follow-up, eyes with nAMD were classified as functional and structural responders and non-responders based on change in visual acuity and macular thickness from baseline to follow-up. Eyes were classified as functional nonresponders if any decrease in BCVA were seen (≥1 ETDRS-letters). In addition, structural nonresponders were defined as no change or increase in macular thickness.
Statistical analyses
Demographic data are presented as median with interquartile range (IQR) for continuous data and as percentage for categorical data. Comparison of the three groups at baseline was done using Kruskal-Wallis equality of populations rank test for continuous data, and chi-square test for categorical data. For statistical significant differences between groups, Wilcoxon rank-sum test was used to identify the group that differed from the two other groups. For continuous data, differences between responders and non-responders were calculated by Wilcoxon rank-sum test, and for categorical data, we used chisquare test. Within-group differences from baseline to follow-up were calculated by Wilcoxon signedrank test for paired data. We tested the association between retinal oxygen saturation and best corrected visual acuity (continuous variables) by using the Pearson correlation coefficient.
Multiple logistic regression analysis was performed with retinal vascular oxygen saturation and calibre as predictors for treatment outcome in a model adjusted for age, sex, smoking, diabetes and time between last injection and follow-up. P-values under 0.05 were defined as statistically significant, and STATA 14.2 (StataCorp, College Station, TX) was used for all statistical tests.
Approvals
The project was approved by the Regional Scientific Ethics Committee (ID S-20160102), and the Danish Data Protection Agency (ID 16/35476). The project was conducted according to the tenets of the Declaration of Helsinki and standard good clinical practice. All participants gave written consent based on both written and oral information prior to inclusion.
Results
A total of 149 eyes from 149 patients were included in the study. Of these, 76 were treatment-naïve eyes with nAMD, 30 were eyes with dry AMD, and 43 were eyes without retinal pathology (Table 1, Figure   2 ). In the nAMD group, 10 eyes did not receive treatment, five eyes were lost during follow-up, retinal imaging at follow-up was not possible in two eyes, and two eyes received two injections and were therefore excluded. Hence, 57 eyes with nAMD were included in the prospective part of the study ( Figure 2 ). All eyes received three injections, and the time between the last injection and follow-up was 37.0 ±13.0 days (median ±IQR).
Patients with treatment-naïve nAMD, dry AMD and normal eyes are compared in Table 1 . The group with normal eyes were younger than the other groups (p<0.01 and p<0.01) and had a lower retinal arteriolar oxygen saturation than patients with nAMD (p=0.02) and dry AMD (p=0.03). In addition, patients with nAMD had lower BCVA as compared to eyes with dry AMD (p<0.01) and normal eyes (p=0.02). The three groups did not differ according to gender, smoking, diabetes, IOP, retinal venular oxygen saturation or retinal vascular calibres.
At baseline, patients who were later classified as functional responders and non-responders did not differ according to age, sex, smoking, diabetes, former cataract surgery, CNV type, BCVA, IOP, and central retinal thickness (Table 2) . However, at follow-up, BCVA was by definition higher among responders as compared to non-responders (70.0 ±24.0 ETDRS letters vs. 56.5 ±23.0 ETDRS letters, p=0.02).
At baseline and follow-up functional responders and non-responders did not differ according to retinal oxygen saturation or vascular calibre, but between baseline and follow-up responders showed a trend towards an increase in retinal arteriolar oxygen saturation (94.3 ±5.4% vs. 95.0 ±4.4%, p=0.05) and decrease in retinal arteriolar calibre (115.3 ±15.0μm vs. 110.5 ±12.3μm, p<0.03) (Table 3) .
At baseline, patients who were stratified as structural responders and non-responders did not differ according to age, sex, smoking, diabetes, former cataract surgery, CNV type, BCVA, and IOP. However, macular thickness was higher in responding than non-responding patients (293.0 ±101.0μm vs. 230.0 ±44.5μm, p<0.01) ( Table 2 ). No differences were found at follow-up between the two groups.
Structural non-responders had an increase in arteriolar and venular oxygen saturation from baseline to follow-up, (arteriolar 93.3 ±3.3 vs. 95.3 ±2.8, p=0.03, venular 59.4 ±11.1 vs. 64.7 ±6.5, p=0.02) and this increment was higher when compared to non-responders (arteriolar 1.6 ± 2.3. vs. 0.5 ± 1.7, p=0.03, venular 3.9 ±7.9 vs. 0.1 ±5.3, p=0.03). In addition, the arteriolar calibre decreased from baseline to follow-up in responders (118.0 ±14.5. vs. 114.3. ±14.5, p=0.01) (Table 3 ).
In a multiple logistic regression model, adjusted for age, sex, smoking, diabetes and time between last injection and follow-up, an increase in retinal venular oxygen saturation associated with a negative initial structural treatment outcome (odds ratio for a full treatment response 1.17 for each 1.0% increment, 95% confidence interval 1.01-1.36, p=0.03, Table 4 ).
Finally, a negative correlation was seen between baseline retinal vascular oxygen saturation and change in retinal macular thickness. Patients with a higher retinal oxygen saturation at baseline had a larger decrease in macular thickness at follow-up (arteriolar p<0.01, venular p=0.03) (Data not shown).
Discussion
In this study, we prospectively demonstrated retinal metabolic and structural alterations as a shortterm response to intravitreal aflibercept therapy in patients with treatment-naïve nAMD.
The retinal arteriolar and venular oxygen saturation were found to increase at follow-up in patients with a negative structural response to the initial treatment. In addition, increased retinal venular oxygen saturation independently associated with a 17% increased risk of an unchanged/higher macular thickness after the loading phase. This could reflect underlying damage of the retinal vasculature induced by the persistent disease activity in patients without a positive treatment response of the initial treatment.
In previous studies, higher retinal venular oxygen saturations have been demonstrated in patients with ischemic macular diseases such as nAMD and diabetic retinopathy (DR) (Geirsdottir et al. 2014; Rilven et al. 2017 ). There might also be higher retinal arteriolar oxygen saturation in such patients, but this has not been demonstrated consistently, potentially due to the ceiling effect of the retinal arteriolar oxygen saturation, which is often close to 100% (Rilven et al. 2017) . The fact that we did find metabolic changes in the retinal arteriolar and venular oxygen saturation could be seen as an expression of the subtle vascular changes seen in nAMD. The disease mechanism should be taken into account when comparing studies of nAMD and DR. In contrast to the disturbances of the choroidal blood supply in AMD, DR affects the inner retina, which is supplied from the retinal circulation (Stefansson et al. 2011) .
In a prospective clinical study, Bek & Jorgensen investigated retinal markers for treatment response in eyes with diabetic macular oedema treated with three injections of ranibizumab (Bek & Jorgensen 2016 ). The authors found that higher mean arterial blood pressure and arteriolar oxygen saturation before treatment was associated with a decrease in visual acuity and an increase in central retinal thickness. In contrast, in nAMD we found higher retinal arteriolar and venular oxygen saturation at baseline to be correlated with a lower macular thickness at follow-up. Furthermore, development of a higher arteriolar oxygen saturation after aflibercept loading associated with a negative structural treatment response.
As far as we know, the concept of retinal oxygen metabolism in nAMD, has only been tested by Geirsdottir et al. that compared retinal oxygen saturation in eyes with nAMD and healthy eyes (Geirsdottir et al. 2014) . They found the retinal venular oxygen saturation to be positively correlated with age in eyes with nAMD (and vice versa in healthy eyes), but in contrast to our study, they found no differences in retinal arteriolar oxygen saturation between eyes with nAMD and healthy eyes.
Geirsdottir et al. points towards a correlation between higher venular oxygen saturation and a more
severe state of nAMD. Methodological differences between the studies could account for the different results.
Several previous studies have investigated the effect of ranibizumab or bevacizumab on retinal vascular calibre in eyes with nAMD, and one recent study has investigated the effect of aflibercept (Tetikoglu et al. 2017) . The latter was a retrospective study that included 15 treatment-naïve eyes with nAMD that were treated with three aflibercept injections with 30 days follow-up after the last injection. They found a statistically significant retinal arteriolar vasoconstriction after treatment, in patients with a positive treatment response, the same results were found in our study. Further comparisons between the studies were not possible, given that only their abstract has been published.
The same pattern was also seen in studies of other VEGF-inhibiting agents. Papadopoulou et al. demonstrated a decrease in retinal arteriolar calibre in nAMD eyes treated with three ranibizumab injections (n=11) (Papadopoulou et al. 2009 ). Fontaine et al. also found a decrease in retinal arteriolar calibre after the first bevacizumab injection, and the decrease was still persistent at the end of the study, five weeks after the third injection (n=23) (Fontaine et al. 2011 ). In the study by Micieli et al., there was a significant decrease in arteriolar calibre in eyes with nAMD, which previously had three or less anti-VEGF injections with ranibizumab, but no change was seen in the group with more than three injections prior to treatment. Only two eyes in the study group were treatment-naïve (n=15) (Micieli et al. 2012 ).
In the study by Mendrionos et al., decreased retinal arteriolar caliber were seen after the first of three injections with ranibizumab, and the difference was still present at 12 months follow-up (n=10) (Mendrinos et al. 2013) . In contrast to these studies, Pekel et al. reported of unchanged retinal vessel calibre three months after three injections with ranibizumab (n=32) (Pekel et al. 2015) .
The two biggest studies investigating the effect of ranibizumab and bevacizumab treatment on the retinal calibre in nAMD eyes were performed by Wickremasinghe et al. (n=88) and Kurt et al. (n=68) (Wickremasinghe et al. 2012; Kurt et al. 2017 ). In the study by Kurt et al., they compared bevacizumab with ranibizumab treatment in eyes with nAMD . Patients were given one injection and followed for one month. They found an arteriolar vasoconstriction in eyes treated with ranibizumab, but not in eyes treated with bevacizumab. No changes were found in the retinal venular calibre in either group. In the study by Wickremasinghe et al., patients with nAMD were treated with three ranibizumab injections and followed for 12 months (Wickremasinghe et al. 2012) . Their study population was very similar to ours according to age (79.1 ±7.9 years) and sex (64.2% females). They found that patients who had decreased visual acuity at follow-up had higher retinal venular calibre at baseline compared to those who had stable or improved visual acuity. No association was found between the arteriolar calibre and treatment outcome.
As in our functional findings, Kurt et al found arteriolar vasoconstriction one week and one month after treatment with ranibizumab, but not bevacizumab, in eyes with nAMD .
As a secondary endpoint, we found the retinal arteriolar oxygen saturation to be higher in AMD (dry and neovascular alike) as compared to healthy eyes, even though the groups were not perfectly balanced according to age. Thus, we cannot conclude if the higher oxygen saturation was caused by the disease or reflected by the higher age in the AMD groups.
Strengths of our study include the prospective design with a strict classification of treatment response based on clinically relevant well-defined criteria. In addition, all patients were treated with the same drug at the same hospital. On the other hand, limitations should be acknowledged. In the prospective part of the study, we only followed patients after the loading phase with no intermediary measurements, the number of participants was limited, and influence by mass significance cannot be ruled out in the statistical analysis. In addition, systemic measurements like arterial blood pressure were not available.
In conclusion, we found higher retinal arteriolar and venular oxygen saturation in patients with a structural negative treatment response, and a decrease in retinal arteriolar calibre in patients with a positive treatment response to aflibercept treatment. Even though retinal metabolism and structure prior to therapy could not be used to predict treatment response after three monthly aflibercept injections, our findings points to a metabolic alteration in eyes with nAMD who do not respond sufficiently. Long-term studies would be needed to tell if this could be used as a potential marker that can be used for clinical guidance in therapy. Flowchart showing the included eyes divided in the three groups (neovascular age-related macular degeneration (AMD), dry AMD and normal eyes). Retinal metabolic and structural measurements as stratified by initial functional and structural response to intravitreal aflibercept loading in patients with treatment-naïve neovascular age-related macular degeneration. 
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